Baseline Values and Sotalol-Induced Changes of Ventricular Repolarization Duration, Heterogeneity, and Instability in Patients With a History of Drug-Induced Torsades de Pointes

被引:23
|
作者
Couderc, Jean-Philippe [1 ]
Kaab, Stefan [2 ]
Hinterseer, Martin [2 ]
McNitt, Scott [1 ]
Xia, Xiaojuan [1 ]
Fossa, Anthony [3 ]
Beckmann, Britt M. [2 ]
Polonsky, Slava [1 ]
Zareba, Wojciech [1 ]
机构
[1] Univ Rochester, Med Ctr, Dept Cardiol, Heart Res Follow Up Program, Rochester, NY 14642 USA
[2] Univ Munich, Klinikum Grosshadern, Dept Med 1, D-8000 Munich, Germany
[3] iCardiac Technol Inc, Rochester, NY USA
关键词
QT interval; Torsades de Pointes; electrocardiogram; sotalol; LONG-QT-SYNDROME; ATRIAL-FIBRILLATION; I-KR; VARIABILITY; INTERVAL; PROARRHYTHMIA; TRIANGULATION; PROLONGATION; TACHYCARDIA; RECORDINGS;
D O I
10.1177/0091270008325927
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The authors investigated whether computerized parameters quantifying ventricular repolarization delay, heterogeneity, and instability characterize individuals who developed drug-induced Torsades de Pointes. Assessing an individual's propensity to Torsades de Pointes when exposed to a QT-prolonging drug is challenging because baseline QT prolongation has limited predictive value. Five-minute digital 12-lead electrocardiograms were acquired at baseline and after a sotalol challenge in 16 patients who had a history of Torsades de Pointes in the context of a QT-prolonging drug and 17 patients who did not have such history. Computerized measurements of QTc, T peak to T end intervals (TpTe), TpTe/QTc, and QT variability were implemented, and novel quantifiers of ventricular repolarization heterogeneity from the early (ERD) and late (LRD) part of the T wave were investigated. Compared with electrocardiograms of patients without a history of Torsades de Pointes, the baseline electrocardiograms of patients with a history of Torsades de Pointes had a longer QTc and an increased repolarization heterogeneity of the early part of the T wave (ERD30%: 44 +/- 13 vs 35 +/- 8 ms, P = .02). On sotalol, the electrocardiograms from individuals with Torsades de Pointes revealed a delay of the terminal part of the T wave that was not present in patients without Torsades de Pointes (TpTe: 27 +/- 40 vs -2 +/- 21 ms, P = .02; LRD70%: 20 +/- 29 vs 2 +/- 4 ms, P = .04). Results suggest that the electrocardiogram abnormalities characterizing patients with a history of Torsades de Pointes are (1) an increased repolarization heterogeneity at baseline and (2) a sotalol-induced prolongation of the terminal part of the T wave.
引用
收藏
页码:6 / 16
页数:11
相关论文
共 50 条
  • [41] Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)
    Poluzzi, Elisabetta
    Raschi, Emanuel
    Moretti, Ugo
    De Ponti, Fabrizio
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 (06) : 512 - 518
  • [42] Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: Torsades de Pointes develops with halothane but not pentobarbital anesthesia
    Weissenburger, J
    Nesterenko, VV
    Antzelevitch, C
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2000, 11 (03) : 290 - 304
  • [43] Transmural Dispersion of Repolarization and Drug-Induced Torsade de Pointes - A 3-D Simulation Study
    Furukawa, Tetsushi
    CIRCULATION JOURNAL, 2011, 75 (01) : 49 - 50
  • [44] Genome Wide Analysis of Drug-Induced Torsades de Pointes: Lack of Common Variants with Large Effect Sizes
    Behr, Elijah R.
    Ritchie, Marylyn D.
    Tanaka, Toshihiro
    Kaeaeb, Stefan
    Crawford, Dana C.
    Nicoletti, Paola
    Floratos, Aris
    Sinner, Moritz F.
    Kannankeril, Prince J.
    Wilde, Arthur A. M.
    Bezzina, Connie R.
    Schulze-Bahr, Eric
    Zumhagen, Sven
    Guicheney, Pascale
    Bishopric, Nanette H.
    Marshall, Vanessa
    Shakir, Saad
    Dalageorgou, Chrysoula
    Bevan, Steve
    Jamshidi, Yalda
    Bastiaenen, Rachel
    Myerburg, Robert J.
    Schott, Jean-Jacques
    Camm, A. John
    Steinbeck, Gerhard
    Norris, Kris
    Altman, Russ B.
    Tatonetti, Nicholas P.
    Jeffery, Steve
    Kubo, Michiaki
    Nakamura, Yusuke
    Shen, Yufeng
    George, Alfred L., Jr.
    Roden, Dan M.
    PLOS ONE, 2013, 8 (11):
  • [45] Targeted Next Generation Exomic Sequencing of Cardiac Electrophysiology Genes in Cases of Drug-Induced Torsades de Pointes
    Ramirez, Andrea H.
    Shaffer, Christian
    Sexton, David P.
    Levy, Shawn
    George, Alfred L.
    Roden, Dan M.
    CIRCULATION, 2010, 122 (21)
  • [46] Drug-Induced QT Prolongation and Torsades de Pointes: An All-Exclusive Relationship or Time for an Amicable Separation?
    Hondeghem, Luc M.
    DRUG SAFETY, 2018, 41 (01) : 11 - 17
  • [47] Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes
    Sager, P. T.
    BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) : 1544 - 1549
  • [48] Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system
    Wu, Ziyang
    Zhou, Pengxiang
    He, Na
    Zhai, Suodi
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [49] Acute canine model for drug-induced torsades de pointes in drug safety evaluation - Influences of anesthesia and validation with quinidine and astemizole
    Yamamoto, K
    Tamura, T
    Imai, R
    Yamamoto, M
    TOXICOLOGICAL SCIENCES, 2001, 60 (01) : 165 - 176
  • [50] Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability
    Vos, M. A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) : 1523 - 1527